Compared: Device Regulations in Japan, China, and UK
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny during a workshop to be held in London on March 20.
The Asia-Pacific Technology Network is organizing the event, with the support of Global Regulatory Services (GRS). Among the speakers will be David Jefferys, MD, Senior Vice-President of Eisai Medical Research and the former Chief Executive and Director of the UK Medical Devices Agency of the Department of Health. He will discuss medical device regulations in Japan, including recent developments and combination products.
By 2017, the global medical device market will be worth around US $434.4 billion, amounting to an annual average growth of 7.1% from 2012, and increasing numbers of devices are hybrids, which combine a device with a medicine, according to the organizers. Pre-filled syringes are an example of a combination product.
“Pharma companies can no longer rely on discovering the next blockbuster, and they are being forced to diversify in order to remain viable; therefore, many are now turning to devices as their next revenue stream. Increasing healthcare costs are helping to drive the growing medical device industry,” they noted in a statement.
For further details on the workshop, contact [email protected]
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
